| Literature DB >> 26900330 |
A Damonti1, L Ferrario1, P Morelli2, M Mussi1, C Patregnani3, E Garagiola1, E Foglia1, R Pagani1, R Carminati3, E Porazzi1.
Abstract
INTRODUCTION: The objective of this paper is the comparison between two different technologies used for the removal of a uterine myoma, a frequent benign tumor: the standard technology currently used, laparoscopy, and an innovative one, colpoceliotomy. It was considered relevant to evaluate the real and the potential effects of the two technologies implementation and, in addition, the consequences that the introduction or exclusion of the innovative technology would have for both the National Health System (NHS) and the entire community.Entities:
Keywords: Colpoceliotomy; HTA; Laparoscopy
Year: 2015 PMID: 26900330 PMCID: PMC4753816
Source DB: PubMed Journal: J Prev Med Hyg ISSN: 1121-2233
Details of the dimensions and the related sub-dimension of the IMPAQHTA model.
| Dimensions | Sub-dimensions |
|---|---|
| General relevance | Quality of scientific evidences |
| Description of the pathology and the related technologies | |
| Safety | Seriousness of Adverse Events (mild, moderate or severe adverse events) |
| Efficacy | Efficacy data |
| Effectiveness | Effectiveness data |
| Economic financial Impact | ABC |
| Health Economic Evaluation | |
| Budget Impact Analysis | |
| Equity | Equity data |
| Legal, social and ethic impact | Legal aspects |
| Social and ethical impact | |
| Organizational Impact | Quantitative impact |
| Qualitative impact |
Description of the sample under assessment.
| Colpoceliotomy | Laparoscopy | P-value | |
|---|---|---|---|
| N. of patients | 118 | 48 | |
| Mean age [years] | 41 | 39 | > 0.005 |
| Length of the procedure [min] | 85 | 80 | > 0.005 |
| Myoma diameters [cm] | 7 | 6 | > 0.005 |
| Myoma dimensions [gr] | 100 | 200 | 0.01 |
| Length of hospitalization | 3 | 5 | 0.000 |
| Adverse events | 1,60% | 6% | 0.000 |
Prioritisation.
| Dimensions | Evaluators | Total | Normalisation | ||||
|---|---|---|---|---|---|---|---|
| # 1 | # 2 | # 3 | # 4 | # 5 | |||
| Safety | 3 | 1 | 1 | 1 | 2 | 1 | 0.222 |
| Economic and financial impact | 1 | 2 | 3 | 3 | 1 | 2 | 0.194 |
| Effectiveness | 2 | 5 | 4 | 5 | 3 | 3 | 0.167 |
| Organisational impact | 5 | 3 | 5 | 2 | 5 | 4 | 0.139 |
| Efficacy | 7 | 7 | 2 | 4 | 4 | 5 | 0.111 |
| General relevance | 6 | 6 | 6 | 6 | 6 | 6 | 0.083 |
| Equity | 4 | 8 | 7 | 7 | 7 | 7 | 0.056 |
| Social and ethical impact | 8 | 4 | 8 | 8 | 8 | 8 | 0.028 |
ABC analysis.
| Phases | Laparoscopy | Colpoceliotomy | ||
|---|---|---|---|---|
| Pre-Hospitalisation | 305.08 € | 17% | 305.08 € | 23% |
| Admission | 65.62 € | 4% | 65.62 € | 5% |
| Pre-Surgery Recovery | 38.93 € | 2% | 38.93 € | 3% |
| Surgery | 1,089.64 € | 61% | 636.37 € | 48% |
| Post-Surgery | 201.83 € | 11% | 201.83 € | 15% |
| Discharge | 88.33 € | 5% | 88.83 € | 7% |
| Total | 1,789.42 € | 100% | 1,336.15 € | 100% |
Cost-effectiveness and Budget Impact Analysis.
| Cost-Effectiveness Value | CCT | STD |
|---|---|---|
| ABC Analysis | €1,336.15 | €1,789.42 |
| Effectiveness data | 98.40% | 94% |
| CEV | 1,357.87 | 1,903.64 |
| Budget Impact Analysis | CCT | STD |
| ABC Analysis | €1,336.15 | €1,789.42 |
| # surgery per year | 118 | 48 |
| Surgery cost per year | € 243,557.30 | € 297,043.55 |
| Further Training cost | €3,870.00 | |
| € 660.80 | ||
| Total Training cost | €4,530.80 | |
| BIA | €248,088.10 | €297,043.55 |
| Δ BIA | -€48,955.45 | €/year |
HTA comparative study.
| Basis score | Normalsed score | Final score | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Dimensions | Sub – dimensions | CCT | STD | TOT | Incidence | CCT | STD | Normalized prioritization | CCT | STD |
| Safety | 2 | 2 | 6 | 1.5 | 0.5 | 0.5 | ||||
| 4 | 0.5 | 0.5 | 0.22 | 0.11 | 0.11 | |||||
| Economic and financial impact | Activity Bases Costing Analysis | 2 | 1 | 6 | 0.7 | 0.2 | 0.1 | |||
| Cost-effectiveness Analysis | 2 | 1 | 6 | 0.7 | 0.2 | 0.1 | ||||
| Budget Impact Analysis | 2 | 1 | 6 | 0.7 | 0.2 | 0.1 | ||||
| 9 | 0.7 | 0.3 | 0.19 | 0.13 | 0.06 | |||||
| Effectiveness | 2 | 1 | 6 | 2.0 | 0.7 | 0.3 | ||||
| 3 | 0.7 | 0.3 | 0.17 | 0.11 | 0.06 | |||||
| Organisational impact | Quantitative Impact | 2 | 1 | 6 | 0.9 | 0.3 | 0.1 | |||
| Qualitative Impact | 2 | 2 | 6 | 0.9 | 0.3 | 0.3 | ||||
| 7 | 0.6 | 0.4 | 0.14 | 0.08 | 0.06 | |||||
| Efficacy | 2 | 2 | 6 | 1.5 | 0.5 | 0.5 | ||||
| 4 | 0.5 | 0.5 | 0.11 | 0.06 | 0.06 | |||||
| General relevance | Consistency of evidence | 1 | 3 | 6 | 0.3 | 0.0 | 0.1 | |||
| Description of technology and comparator | 1 | 2 | 6 | 0.3 | 0.0 | 0.1 | ||||
| Safety of the new technology and comparator | 2 | 2 | 6 | 0.3 | 0.1 | 0.1 | ||||
| Target Population | 2 | 1 | 6 | 0.3 | 0.1 | 0.0 | ||||
| Consistency of the objectives with the adopted strategy | 2 | 2 | 6 | 0.3 | 0.1 | 0.1 | ||||
| Potential advantaged areas | 2 | 2 | 6 | 0.3 | 0.1 | 0.1 | ||||
| 22 | 0.5 | 0.5 | 0.08 | 0.04 | 0.05 | |||||
| Equity | 2 | 3 | 6 | 1.2 | 0.4 | 0.6 | ||||
| 5 | 0.4 | 0.6 | 0.06 | 0.02 | 0.03 | |||||
| Social and ethical impact | Ethical Impact | 3 | 2 | 6 | 0.6 | 0.3 | 0.2 | |||
| Social Impact | 3 | 2 | 6 | 0.6 | 0.3 | 0.2 | ||||
| 10 | 0.6 | 0.4 | 0.03 | 0.02 | 0.01 | |||||
Fig. 1.Organizational impact.